News & Updates

Doron Therapeutics has initiated its Phase 3 clinical trial for MOTYS (PTP-001), dosing the first patients in a global study aimed at evaluating the efficacy of this injectable biologic therapy for knee osteoarthritis. This milestone marks a significant step forward in bringing this innovative treatment to patients...

Doron Therapeutics has completed a successful End-of-Phase 2 and initial RMAT meeting with the FDA, confirming the Phase 3 clinical program's design and scope for MOTYS in treating knee osteoarthritis. This productive dialogue with the FDA provides clear guidance for our pivotal trials...

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to MOTYS, Doron Therapeutics' lead placental tissue-derived biologic, recognizing its potential to address unmet medical needs in knee osteoarthritis treatment. This designation provides expedited development and review opportunities...

Doron Therapeutics has successfully raised $11 million in a Series A funding round led by SPRIM Global Investments, aiming to advance MOTYS into Phase 3 clinical studies for symptomatic knee osteoarthritis. This investment strengthens our financial position and accelerates our path to bringing MOTYS to market...